TickerTalks
Browse all tickers →
TickerTalks›$ECOR
ECECOR

electroCore, Inc.

$ECOR·$55M·Medical - Devices·Healthcare
$5.88+1.7%YTD+31.0%1Y-20.4%
Mentions · last 7 days
2026-07-10: 11 posts2026-07-11: 13 posts2026-07-12: 16 posts2026-07-13: 12 posts2026-07-14: 12 posts2026-07-15: 11 posts2026-07-16: 18 posts93-5%
Price updated 57m ago·X counts updated 1d ago
ECECOR
$ECORelectroCore, Inc.
$5.88+1.73%93 posts-5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ECOR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

electroCore up 34% YTD — nano-cap vagus-nerve-stimulation device with real Q1 growth acceleration.

electroCore develops non-invasive vagus-nerve-stimulation (nVNS) medical devices — the specific gammaCore product treating migraine and other neurological conditions. The stock is up 34% YTD as commercial revenue accelerates.

  • Revenue grew 43% YoY last quarter with a -55% operating margin — real top-line acceleration but continued operating losses; the equity value depends on continued commercial ramp.
  • Trades at 2.1x TTM sales with negative TTM P/E on cyclical losses — reasonable multiples for a small-cap medtech; the $55M market cap reflects continued commercial-launch execution.
  • Zero insider transactions in the last 60 days at 29th percentile of 52-week range — clean absence of distributing signal at the current levels.
  • The Frontiers in Neuroscience review article synthesizing evidence for cervical nVNS activating the vagus nerve is real clinical-mechanism validation.
  • 52-week position 29th percentile with position vs 200-day MA -4% — the tape is coiling in the mid-lower range; the community's $16-$18 target zone captures the specific technical framing.

August 5 Q2 earnings is where the commercial-launch story either extends or contracts: revenue growth held above 40% plus specific commentary on commercial-payer coverage is what turns coiling into acceleration; a modest print with cautious guide is where the tape drifts back to $5. Real nano-cap medtech with real commercial acceleration — the setup rewards continued execution and the community's 'no resistance above $10' framing captures the setup dynamics.

Agrees with X sentimentThe bullish X take on electroCore as a ~$50M market cap micro-cap with hyper-growth and pure-margin Q1 results, the recent insider buying, and the $16-$18 zone target is analytically fair on the small-cap medtech setup. The 'large TAM + unmet need + tipping-point adoption' framework is a legitimate framework.

What to watch: Aug 5 Q2 earnings — need revenue growth held above 40% and specific commentary on commercial-payer coverage. A modest print with cautious guide is where the tape drifts back to $5.

On the calendar: 2026-08-05 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-06-02

electroCore chatter centers on a ~$50M market cap micro-cap with hyper-growth and pure-margin Q1 results, plus recent insider buying. Contributors target a $16-$18 zone (described as 'no resistance' above the recent $10 psychological-resistance break). The medtech 'large TAM + unmet need + tipping-point adoption + profitability inflection' framework is described as triggering for ECOR. The Annual General Meeting on June 4 is the upcoming catalyst; tone is broadly bullish micro-cap accumulation.

Read the AI verdict + X sentiment for $ECOR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes non-invasive vagus nerve stimulators (gammaCore) for rheumatoid arthritis, PTSD, cluster headache, and migraine treatment.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $ECOR.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

What this means for $ECOR

Neutral — Makes non-invasive vagus nerve stimulators (gammaCore) for rheumatoid arthritis, PTSD, cluster headache, and migraine treatment; the surgical robotics procedure growth and AI-enabled device adoption does not materially affect this business's near-term earnings.

Industry benchmark

13-name peer basket
-16.5%YTD
-4.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-379%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-42.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-9.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
8.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
87.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 6, 2026$-0.59$-0.590.0%
Q4 2025Mar 19, 2026$-0.34$-0.35+2.9%
Q3 2025Nov 5, 2025$-0.40$-0.36-11.1%
Q2 2025Aug 6, 2025$-0.35$-0.32-9.4%
Next earningsWed, Aug 5·consensus EPS $-0.41

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$9.6M+42.6%87.3%-55.5%$-0.59$-3.0M
Q4 FY25$9.2M+31.2%88.4%-31.8%$-0.38$-1.5M
Q3 FY25$8.7M+32.6%86.0%-33.2%$-0.40$-1.7M
Q2 FY25$7.4M+20.2%87.3%-47.5%$-0.44$-648K

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$41.9M$41.0M – $42.8M-$1.50-$1.55 – -$1.454
FY27$53.9M$52.6M – $55.2M-$0.42-$0.48 – -$0.374
FY28$70.0M$69.6M – $70.4M$0.56-$0.14 – $1.264
FY29$74.8M$72.5M – $77.3M$0.36$0.35 – $0.383
FY30$87.0M$84.4M – $90.0M$0.90$0.86 – $0.943

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.26%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-26.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 5.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.895-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 28Joshua S. LevCFO6.7K sh$60KSellMay 22Joshua S. LevCFO3.0K sh$20KBuyMay 21Thomas J. ErricoDirector10.0K sh$60KSellApr 10Daniel S GoldbergerFormer Officer and Director16.1K sh$97K
+ 6 other (4 awards · 1 small · 1 inthemoney) in window

See when $ECOR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsApr 143
AI summary

A new insider of electroCore, Inc. (ECOR) filed Form 3 with no securities beneficially owned as of April 14, 2026, with the signing done by attorney-in-fact John L. Cleary, II. This is a routine initial Section 16 ownership statement for a new insider appointment at electroCore.

8-KPress release / Reg FDJan 208-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 7 other (2 earnings 8-Ks · 1 10-Q · 1 13G · 1 D) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulationglobenewswire.com·2d agoelectroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcriptseekingalpha.com·24d agoelectroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conferenceglobenewswire.com·31d agoRBC reiterates 'outperform' on Ecora Royalties after Voisey's Bay site visit boosts confidenceproactiveinvestors.co.uk·33d agoFrontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgeryglobenewswire.com·39d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABT$BSX$ISRG$BFLY$TMDX$BIO$PRCT$CLPT
Voices on X · last 7 days

No standout posts about $ECOR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport